Increased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering.
Peripheral blood-derived endothelial cells (pBD-ECs) are an attractive tool for cell therapies and tissue engineering, but have been limited by their low isolation yield. We increase pBD-EC yield via administration of the chemokine receptor type 4 antagonist AMD3100, as well as via a diluted whole blood incubation (DWBI).Porcine pBD-ECs were isolated using AMD3100 and DWBI and tested for EC markers, acetylated LDL uptake, growth kinetics, metabolic activity, flow-mediated nitric oxide production and seeded onto titanium tubes implanted into vessels of pigs.DWBI increased the yield of porcine pBD-ECs 6.6-fold, and AMD3100 increased the yield 4.5-fold. AMD3100-mobilized ECs were phenotypically indistinguishable from nonmobilized ECs. In porcine implants, the cells expressed endothelial nitric oxide synthase, reduced thrombin-antithrombin complex systemically and prevented thrombosis.Administration of AMD3100 and the DWBI method both increase pBD-EC yield.
Jamiolkowski, RM; Kang, SD; Rodriguez, AK; Haseltine, JM; Galinat, LJ; Jantzen, AE; Carlon, TA; Darrabie, MD; Arciniegas, AJ; Mantilla, JG; Haley, NR; Noviani, M; Allen, JD; Stabler, TV; Frederiksen, JW; Alzate, O; Keil, LG; Liu, S; Lin, F-H; Truskey, GA; Achneck, HE
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Digital Object Identifier (DOI)